Recent Updates
Recently added Catalysts
XENE Positive Sentiment Score: 75/100

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Key Takeaway: Xenon Pharmaceuticals Inc. has announced its participation in the Goldman Sachs 44th Annual Global Healthcare Conference, which will take place on June 12, 2023. The presentation will feature key executives, including President and CEO Ian Mortimer and CFO Sherry Aulin. A live webcast will be available for investors, and the content will be accessible for replay after the event. Xenon is focused on developing therapeutics for neurological disorders, addressing significant unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Xenon Pharmaceuticals is presenting at a reputable conference, enhancing its visibility.
  • The company focuses on high unmet medical needs in neurology, specifically epilepsy, showing dedication to patient care.

Full Press Release Details

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.
Company Fireside Chat Presentation Details:
Date: Monday, June 12, 2023
Time: 10:00 am Pacific Time (1:00 pm Eastern Time)
Webcast: Register here
Presenters: Ian Mortimer, President and CEO Sherry Aulin, CFO
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Xenon Pharmaceuticals Inc.

Frequently Asked Questions

When will Xenon Pharmaceuticals present at the Goldman Sachs conference?

Xenon Pharmaceuticals will present on June 12, 2023.

Who will present on behalf of Xenon Pharmaceuticals?

Ian Mortimer, CEO, and Sherry Aulin, CFO, will present.

Where can I watch Xenon's presentation live?

The presentation will be available on Xenon's website under the 'Investors' section.

What is the main focus of Xenon Pharmaceuticals?

Xenon Pharmaceuticals focuses on developing therapies for neurological disorders.

What is the primary area of medical need for Xenon?

Xenon specifically targets therapies for epilepsy.

Last updated: Jun 6, 2023